Resumen
[0001] The present invention refers to a specific composition, which functions as an enzyme mimic or artificial enzyme, for assessing the presence of microorganisms in a test sample. On the other hand, the composition can be used as a medicament, preferably in the treatment of infections caused by said microorganisms. [0002] The composition comprises: [0003] a) a coordination polymer which in turn comprises a polymeric crystalline structure with a repeating core characterized by Formula I: M2L2(H20)4 wherein: [0004] i. M is copper (II) metal ion, [0005] ii. L is an aromatic pseudo-peptide characterized by Formula II: H2I-bis-amino acid or Formula III: H2T-bis-amino acid, wherein T is terephthaloyl, I is isophthaloyl, and the amino acid is a L or D amino acid; and [0006] b) H2O2.
Reivindicaciones
1. A composition comprising: a) A coordination polymer which in turn comprises a polymeric crystalline structure with a repeating core characterized byFormula I:M2L2 (H<2>O)<4> wherein: i. M is copper (II) metal ion, ii. L is an aromatic pseudo-peptide characterized byFormula II: H<2>I -bis-amino acid or Formula III: H<2>T -bis-amino acid, wherein T is Terephthaloyl, I is Isophthaloyl, and the amino acid is a L or D amino acid; and b) H<2>O<2>. 2. Composition, according to claim 1, wherein L is an aromatic pseudo-peptide selected from the group comprising: H<2>T -bis-L-aspartate, H<2>T -bis-D-aspartate; H<2>T -bis-L-alanine, H<2>T -bis-D-alanine; H<2>T -bis-L-valine, H<2>T -bis-D-valine, H<2>T -bis-L-isoleucine, H<2>T -bis-D-isoleucine, H<2>T -bis-L-leucine, H<2>T -bis-D-leucine, H<2>T -bis-L-phenylalanine, H<2>T -bis-D-phenylalanine, H<2>T -bis-β-alanine, H<2>T -bis- β-alanine; H<2>I bis β-alanine H<2>I -bis-L-aspartate, H<2>I -bis-D-aspartate; H<2>I -bis-L-alanine, H<2>I -bis-D-alanine; H<2>I -bis-L-valine, H<2>I -bis-D-valine, H<2>I -bis-L-isoleucine, H<2>I -bis-D-isoleucine, H<2>I -bis-L-leucine, H<2>I -bis-D-leucine, H<2>I -bis-L- phenylalanine, H<2>I -bis-D-phenylalanine, H<2>I -bis-β-alanine or H<2>T -bis- β-alanine, wherein T is Terephthaloyl, I is Isophthaloyl. 3. Composition, according to any of the claims 1 or 2, comprising: a) A coordination polymer which in turn comprises a polymeric crystalline structure with a repeating core characterized byFormula I:M2L2 (H<2>O)<4> wherein: i. M is copper (II) metal ion, ii. L is H<2>-Isophthaloyl-bis-β-alanine; and b) H<2>O<2>. 4. Composition, according to any of the claims 1 to 3, characterized in that the polymeric crystalline structure of Formula I is in the form of a composite material wherein the polymeric crystalline structure of Formula I is embedded in an organic matrix. 5. Composition, according to any of the claims 1 to 4, wherein the organic matrix is selected from: polyethylene glycol, agarose, polyacrylamide, cellulose, fiber, gelatin or chitosan. 6. Composition, according to any of the claims 1 to 5, characterized in that the polymeric crystalline structure of Formula I is in the form of a mouldable gelatin. 7. Pharmaceutical composition comprising the composition of any of the claims 1 to 6 and, optionally, pharmaceutically acceptable excipient or carriers. 8. Use of the composition of any of the claims 1 to 6 for assessing the presence of a catalase-positive microorganism in a test sample, by means of the identification of the inhibition of the microorganism, wherein the composition exerts a growth-inhibiting effect on the microorganism. 9. Use of the composition of any of the claims 1 to 6, according to claim 8, for assessing the presence of a catalase and oxidase-positive aerobic or anaerobic microorganism in a test sample, by means of the identification of the inhibition of the microorganism, wherein the composition exerts a growth-inhibiting effect on the microorganism. 10. Use of the composition of any of the claims 1 to 6, according to any of the claims 8 or 9, wherein the catalase-positive microorganism is a bacterium pertaining to a genus selected from: Sphingobacterium, Alcaligenes or Bacillus. 11. Use of the composition of any of the claims 1 to 6, according to any of the claims 8 to 10, wherein the catalase-positive microorganism is a bacterium selected from: Sphingobacterium spiritivorum, Alcaligenes faecalis or Bacillus cereus. 12. Method for assessing the presence of a catalase-positive microorganism in a test sample by means of the identification of the inhibition of the microorganism, which comprises: a) Spreading the composition of any of the claims 1 to 6 over the test sample, and b) Wherein the identification of a zone of inhibition in the test sample is indicative of the inhibition of the microorganism. 13. Method, according to claim 12, for assessing the presence of a catalase and oxidase aerobic or anaerobic microorganism in a test sample by means of the identification of the inhibition of the microorganism, which comprises: a) Spreading the composition of any of the claims 1 to 6 over the test sample, and b) Wherein the identification of a zone of inhibition in the test sample is indicative of the inhibition of the microorganism. 14. Method, according to any of the claims 12 or 13, wherein the catalase-positive microorganism is a bacterium pertaining to a genus selected from: Sphingobacterium, Alcaligenes or Bacillus, preferably a bacterium selected from: Sphingobacterium spiritivorum, Alcaligenes faecalis or Bacillus cereus. 15. Pharmaceutical composition of claim 7 for use as a medicament, preferably in the treatment of a bacterial infection.
